Jingrong Jean Cui Sells 18,500 Shares of Turning Point Therapeutics (NASDAQ:TPTX) Stock

Turning Point Therapeutics (NASDAQ:TPTX) Director Jingrong Jean Cui sold 18,500 shares of the stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $62.94, for a total transaction of $1,164,390.00. Following the sale, the director now owns 1,301,298 shares of the company’s stock, valued at approximately $81,903,696.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Jingrong Jean Cui also recently made the following trade(s):

  • On Wednesday, February 12th, Jingrong Jean Cui sold 18,500 shares of Turning Point Therapeutics stock. The stock was sold at an average price of $65.92, for a total value of $1,219,520.00.
  • On Wednesday, January 29th, Jingrong Jean Cui sold 7,000 shares of Turning Point Therapeutics stock. The shares were sold at an average price of $58.73, for a total value of $411,110.00.
  • On Monday, January 27th, Jingrong Jean Cui sold 7,000 shares of Turning Point Therapeutics stock. The shares were sold at an average price of $57.66, for a total value of $403,620.00.
  • On Wednesday, January 15th, Jingrong Jean Cui sold 11,500 shares of Turning Point Therapeutics stock. The shares were sold at an average price of $53.12, for a total value of $610,880.00.
  • On Monday, January 13th, Jingrong Jean Cui sold 18,500 shares of Turning Point Therapeutics stock. The stock was sold at an average price of $52.87, for a total value of $978,095.00.
  • On Friday, January 10th, Jingrong Jean Cui sold 18,500 shares of Turning Point Therapeutics stock. The shares were sold at an average price of $57.68, for a total value of $1,067,080.00.
  • On Friday, December 20th, Jingrong Jean Cui sold 11,500 shares of Turning Point Therapeutics stock. The shares were sold at an average price of $63.40, for a total value of $729,100.00.
  • On Wednesday, December 18th, Jingrong Jean Cui sold 18,500 shares of Turning Point Therapeutics stock. The stock was sold at an average price of $59.20, for a total value of $1,095,200.00.
  • On Monday, December 16th, Jingrong Jean Cui sold 11,500 shares of Turning Point Therapeutics stock. The stock was sold at an average price of $58.35, for a total value of $671,025.00.
  • On Friday, December 13th, Jingrong Jean Cui sold 11,500 shares of Turning Point Therapeutics stock. The stock was sold at an average price of $55.75, for a total value of $641,125.00.

TPTX opened at $61.08 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 36.64 and a quick ratio of 36.64. The business has a 50 day simple moving average of $60.33 and a 200-day simple moving average of $49.50. Turning Point Therapeutics has a 12 month low of $24.21 and a 12 month high of $67.54.

Several institutional investors have recently bought and sold shares of TPTX. Cutler Group LP grew its holdings in Turning Point Therapeutics by 100.0% during the fourth quarter. Cutler Group LP now owns 600 shares of the company’s stock worth $37,000 after acquiring an additional 300 shares during the period. Rhumbline Advisers lifted its holdings in Turning Point Therapeutics by 15.7% in the third quarter. Rhumbline Advisers now owns 6,729 shares of the company’s stock valued at $253,000 after acquiring an additional 911 shares during the period. Tower Research Capital LLC TRC boosted its position in shares of Turning Point Therapeutics by 155.4% during the 3rd quarter. Tower Research Capital LLC TRC now owns 1,548 shares of the company’s stock worth $58,000 after purchasing an additional 942 shares in the last quarter. Great West Life Assurance Co. Can purchased a new stake in shares of Turning Point Therapeutics during the 4th quarter worth $77,000. Finally, Bank of America Corp DE boosted its position in shares of Turning Point Therapeutics by 14.3% during the 4th quarter. Bank of America Corp DE now owns 10,312 shares of the company’s stock worth $642,000 after purchasing an additional 1,287 shares in the last quarter. Hedge funds and other institutional investors own 67.23% of the company’s stock.

A number of research firms recently weighed in on TPTX. Zacks Investment Research upgraded shares of Turning Point Therapeutics from a “hold” rating to a “buy” rating and set a $49.00 price objective on the stock in a research report on Friday, November 8th. Roth Capital started coverage on shares of Turning Point Therapeutics in a research report on Thursday, November 14th. They set a “buy” rating and a $65.00 price objective for the company. Finally, HC Wainwright restated a “buy” rating and issued a $70.00 target price on shares of Turning Point Therapeutics in a research note on Tuesday, January 21st. Eleven analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and an average price target of $55.00.

Turning Point Therapeutics Company Profile

Turning Point Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in designing and developing novel small molecule targeted oncology therapies. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients.

Featured Story: Bid-Ask Spread

Insider Buying and Selling by Quarter for Turning Point Therapeutics (NASDAQ:TPTX)

Receive News & Ratings for Turning Point Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Turning Point Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.